Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A single ascending dose study in healthy humans†

By Asai Fumitoshi   Jakubowski Joseph A.   Naganuma Hideo   Brandt John T.   Matsushima Nobuko   Hirota Takashi   Freestone Stephen   Winters Kenneth J.  

Platelets, Vol. 17, Iss. 4, 2006-06 ,pp. : 209-217

Informa Healthcare

Access to resources Recommend Favorite

Prasugrel, a Platelet P2Y₁₂ Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 4, 2016-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses

By Judge Heather   Buckland Robert   Sugidachi Atsuhiro   Jakubowski Joseph   Storey Robert  

Platelets, Vol. 19, Iss. 2, 2008-03 ,pp. : 125-133

Informa Healthcare

Access to resources Recommend Favorite

Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes

By Behan Miles W. H.   Fox Susan C.   Heptinstall Stan   Storey Robert F.  

Platelets, Vol. 16, Iss. 2, 2005-03 ,pp. : 73-80

Informa Healthcare

Access to resources Recommend Favorite

P2Y12 receptor in platelet activation

By Kim Soochong   Kunapuli Satya P.  

Platelets, Vol. 22, Iss. 1, 2011-02 ,pp. : 54-58

Informa Healthcare

Access to resources Recommend Favorite